BioSpace News Archive

Gilead Sciences, Inc. announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company’s investigational, novel inhibitor of HIV-1 capsid function, lenacapavir, sustained predicted therapeutic concentrations for at least six months following a single 900 mg dose.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Older Adults With Diabetes, Hypertension, Cardiovascular Disease, and Dyslipidemia Maintained High Rates of Virologic Suppression After Switching to Biktarvy